Bogdanski Aleksander M, van Hooft Jeanin E, Boekestijn Bas, Bonsing Bert A, Wasser Martin N J M, Klatte Derk C F, van Leerdam Monique E
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Fam Cancer. 2024 Aug;23(3):323-339. doi: 10.1007/s10689-024-00368-1. Epub 2024 Apr 15.
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths and is associated with a poor prognosis. The majority of these cancers are detected at a late stage, contributing to the bad prognosis. This underscores the need for novel, enhanced early detection strategies to improve the outcomes. While population-based screening is not recommended due to the relatively low incidence of PDAC, surveillance is recommended for individuals at high risk for PDAC due to their increased incidence of the disease. However, the outcomes of pancreatic cancer surveillance in high-risk individuals are not sorted out yet. In this review, we will address the identification of individuals at high risk for PDAC, discuss the objectives and targets of surveillance, outline how surveillance programs are organized, summarize the outcomes of high-risk individuals undergoing pancreatic cancer surveillance, and conclude with a future perspective on pancreatic cancer surveillance and novel developments.
胰腺导管腺癌（PDAC）是癌症相关死亡的主要原因，且预后较差。这些癌症大多在晚期被发现，这导致了不良预后。这凸显了需要新的、更有效的早期检测策略来改善治疗结果。虽然由于PDAC发病率相对较低，不建议进行基于人群的筛查，但由于疾病发病率增加，建议对PDAC高危个体进行监测。然而，高危个体胰腺癌监测的结果尚未明确。在本综述中，我们将阐述PDAC高危个体的识别，讨论监测的目标和对象，概述监测项目的组织方式，总结接受胰腺癌监测的高危个体的结果，并以对胰腺癌监测和新进展的未来展望作为结论。
